Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Xeris Biopharma Holdings
(NASDAQ:XERS)
Intraday
$1.76
-0.02
[-1.12%]
After-Hours
$1.76
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.76
-0.02
[-1.12%]
At close: Apr 24
$1.76
0
[0.00%]
After Hours: 4:07PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Xeris Biopharma Holdings Stock (NASDAQ:XERS)
Xeris Biopharma Holdings Stock (NASDAQ: XERS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 28, 2024
Xeris Biopharma Holdings shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $5.
Benzinga Newsdesk
-
Mar 28, 2024, 7:12AM
Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5
Benzinga Newsdesk
-
Mar 28, 2024, 6:51AM
Thursday, March 07, 2024
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $6
Benzinga Newsdesk
-
Mar 7, 2024, 6:13AM
Wednesday, March 06, 2024
Xeris Biopharma Holdings shares are trading lower after the company reported Q4 financial results.
Benzinga Newsdesk
-
Mar 6, 2024, 10:54AM
Xeris Biopharma Expects 2024 Revenue Of $170M-$200M Versus Consensus Of $184.11M; Year-End Cash, Cash Equivalents, And Short-term Investments Of $55M-$75M
Benzinga Newsdesk
-
Mar 6, 2024, 7:08AM
Xeris Biopharma Holdings Q4 GAAP EPS $(0.10), Inline, Sales $44.39M Beat $43.55M Estimate
Benzinga Newsdesk
-
Mar 6, 2024, 7:04AM
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Benzinga Newsdesk
-
Mar 6, 2024, 7:01AM
Earnings Scheduled For March 6, 2024
Benzinga Insights
-
Mar 6, 2024, 5:00AM
Tuesday, March 05, 2024
Earnings Outlook For Xeris Biopharma Holdings
Benzinga Insights
-
Mar 5, 2024, 12:01PM
Wednesday, January 10, 2024
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Jan 10, 2024, 1:06PM
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
Benzinga Newsdesk
-
Jan 10, 2024, 8:02AM
Thursday, January 04, 2024
Xeris Biopharma shares are trading higher after the company updated its outlook for full year 2023.
Benzinga Newsdesk
-
Jan 4, 2024, 10:59AM
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Jan 4, 2024, 10:12AM
Xeris Biopharma Sees FY23 Revenue At High End Of Previous Guidance Of $160M-$165M Vs. Estimate Of $161.96M; Expects To Be Cash Flow Positive In Q4
Benzinga Newsdesk
-
Jan 4, 2024, 7:12AM
Monday, November 13, 2023
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Lowers Price Target to $5.5
Benzinga Newsdesk
-
Nov 13, 2023, 6:27PM
Friday, November 10, 2023
Piper Sandler Maintains Overweight on Xeris Biopharma Holdings, Lowers Price Target to $4-Report released on 9th Nov 2023
Benzinga Newsdesk
-
Nov 10, 2023, 5:21PM
Piper Sandler Maintains Overweight on Xeris Biopharma Holdings, Lowers Price Target to $4
Benzinga Newsdesk
-
Nov 10, 2023, 5:20PM
Thursday, November 09, 2023
Xeris Biopharma Says Confident To Achieve Cash Flow Breakeven In Q4
Benzinga Newsdesk
-
Nov 9, 2023, 7:23AM
Xeris Biopharma Tightens 2023 Revenue Guidance From $155M-$165M To $160M-$165M
Benzinga Newsdesk
-
Nov 9, 2023, 7:22AM
Xeris Biopharma Holdings Q3 EPS $(0.09) Vs. $(0.16) Last Year, Sales $48.32M Beat $41.08M Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 7:05AM
Earnings Scheduled For November 9, 2023
Benzinga Insights
-
Nov 9, 2023, 6:52AM
Monday, October 16, 2023
Xeris Biopharma shares are trading higher after the company tightened FY23 revenue guidance and raised 2023 cash, cash equivalents and short-term investment guidance.
Benzinga Newsdesk
-
Oct 16, 2023, 12:44PM
Why Xeris Biopharma Shares Are Trading Higher Today
Lekha Gupta
-
Oct 16, 2023, 9:25AM
Xeris Biopharma's 2023 Cash Utilization Expected To Be $52M-$57M
Benzinga Newsdesk
-
Oct 16, 2023, 7:07AM
Xeris Biopharma Tightens FY23 Revenue Guidance From $145M-$165M To $155M-$165M Versus Consensus Of $158.2M; Raises 2023 Cash, Cash Equivalents, And Short-Term Investment Guidance From $55M-$65M to $65M-$70M
Benzinga Newsdesk
-
Oct 16, 2023, 7:06AM
Wednesday, September 27, 2023
Xeris Biopharma Entered Into Exchange Agreements For Its 5.00% Convertible Senior Notes Due 2025, To Exchange $31.975M Of The Existing Notes For $33.574M Of Xeris' New 8.00% Convertible Senior Notes Due 2028
Benzinga Newsdesk
-
Sep 27, 2023, 8:13AM
Monday, August 28, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Benzinga Insights
-
Aug 28, 2023, 11:00AM
Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $4.5
Benzinga Newsdesk
-
Aug 28, 2023, 9:32AM
Thursday, August 10, 2023
$8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
Aug 10, 2023, 8:33AM
Wednesday, August 09, 2023
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Benzinga Newsdesk
-
Aug 9, 2023, 6:42AM
Tuesday, August 08, 2023
Xeris Biopharma Revises FY23 Revenue Outlook To $145M - $165M From $135M to $165M Vs. $149.35M Est.
Benzinga Newsdesk
-
Aug 8, 2023, 7:05AM
Xeris Biopharma Holdings Q2 EPS $(0.14) Misses $(0.13) Estimate, Sales $36.89M Beat $34.84M Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 4:48AM
Monday, August 07, 2023
Earnings Outlook For Xeris Biopharma Holdings
Benzinga Insights
-
Aug 7, 2023, 2:01PM
Thursday, June 29, 2023
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
Lisa Levin
-
Jun 29, 2023, 11:23AM
Wednesday, June 21, 2023
Xeris Biopharma Announces First Participant Dosed In A Phase 2 Clinical Study Of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) In Patients With Hypothyroidism
Bill Haddad
-
Jun 21, 2023, 7:11AM
Wednesday, May 10, 2023
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Benzinga Newsdesk
-
May 10, 2023, 1:20PM
Tuesday, May 09, 2023
Xeris Biopharma shares are trading higher after the company reported better-than-expected Q1 financial results.
Benzinga Newsdesk
-
May 9, 2023, 12:14PM
Xeris Biopharma Affirms FY23 Guidance
Benzinga Newsdesk
-
May 9, 2023, 7:10AM
Xeris Biopharma Holdings Q1 EPS $(0.12) Beats $(0.17) Estimate, Sales $33.20M Beat $30.76M Estimate
Benzinga Newsdesk
-
May 9, 2023, 7:09AM
Earnings Scheduled For May 9, 2023
Benzinga Insights
-
May 9, 2023, 6:03AM
Tuesday, April 18, 2023
Xeris Biopharma Announces Issuance Of US Patent Covering XeriSol Formulations
Benzinga Newsdesk
-
Apr 18, 2023, 7:00AM
Thursday, March 30, 2023
Xeris Biopharma Announces Research Evaluation Collaboration And Option Agreement With Regeneron For XeriJect
Bill Haddad
-
Mar 30, 2023, 7:18AM
Thursday, March 09, 2023
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Benzinga Newsdesk
-
Mar 9, 2023, 6:19AM
Wednesday, March 08, 2023
Xeris Biopharma Expects FY23 Revenues Of $135M-$165M Vs. $152.31M Estimate
Benzinga Newsdesk
-
Mar 8, 2023, 6:08AM
Xeris Pharmaceuticals Q4 EPS $(0.10) Beats $(0.16) Estimate, Sales $33.14M Beat $31.04M Estimate
Benzinga Newsdesk
-
Mar 8, 2023, 6:01AM
Earnings Scheduled For March 8, 2023
Benzinga Insights
-
Mar 8, 2023, 4:42AM
Tuesday, March 07, 2023
Xeris Pharmaceuticals's Earnings Outlook
Benzinga Insights
-
Mar 7, 2023, 12:01PM
Monday, January 30, 2023
Xeris Biopharma Announces FDA Has Granted Orphan-Drug Exclusivity For Recorlev
Bill Haddad
-
Jan 30, 2023, 7:02AM
Friday, January 27, 2023
SVB Leerink Maintains Outperform on Xeris Biopharma Holdings, Lowers Price Target to $5
Benzinga Newsdesk
-
Jan 27, 2023, 6:50AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch